Biospecimen Issues:
For Researchers
Overview
To conduct correlative science studies, biospecimen samples are needed. These samples are donated by patients and are taken from tumor tissue, cheek (also called buccal) swabs, blood serum, plasma, needle biopsies or urine. These samples need to be obtained from both cancer patients and healthy people so that comparison research can be conducted.
The emergence of regulations for establishing, maintaining and using biobanks (places to store biospecimens) is forcing issues concerning sample collection, storage, processing and ethical considerations to the forefront.
Unfortunately, the vast majority of the millions of biospecimens in collections around the world are not suitable for making the type of apples-to-apples comparisons that modern cancer biology research demands.
The reason samples are unsuitable is simple, there are no standards for:
- How surgeons collect tissue samples
- How pathologists prepare (process) those biospecimens
- How biobanks store their collected biospecimens
- How biobanks distribute samples
- How researchers analyze the samples
Given the exquisite sensitivity of today's analytical techniques, it is nearly impossible to distinguish between molecular fingerprints that are related to cancer and those created by the way a given biospecimen was handled.
As mentioned previously, in order to correct this problem, the National Cancer Institute (NCI) created the Office of Biorepositories and Biospecimen Research (OBBR) to spearhead and coordinate a strategic plan to evaluate and standardize its funded biospecimen resources and the quality of biospecimens used in cancer research.
With the help of the OBBR, the NCI has since developed a set of standards published as the National Cancer Institute Best Practices for Biospecimen Resources.
For
more information, please visit:
http://biospecimens.cancer.gov/practices/ or https://cabig.nci.nih.gov